Blocking the ATR/CHK1 DNA repair pathway makes cytarabine more effective at killing cancer cells with 9p21 loss, without increasing harm to cells without the deletion, suggesting a targeted way to improve treatment.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether adding ATR/CHK1 inhibitors to cytarabine improves survival in patients with 9p21-loss tumors compared to cytarabine alone.
A systematic review and meta-analysis of all published clinical trials (n≥6) evaluating cytarabine + ATR/CHK1 inhibitors in patients with 9p21-loss solid tumors, with standardized genetic confirmation, primary endpoints of overall survival and progression-free survival, and subgroup analysis by tumor type.
An RCT could determine whether adding an ATR inhibitor to cytarabine improves outcomes in patients with 9p21-loss bladder cancer.
A multicenter, double-blind RCT of 220 patients with advanced 9p21-loss bladder cancer randomized to cytarabine + ATR inhibitor (e.g., berzosertib 30 mg/m² IV) vs. cytarabine + placebo, with primary endpoint of progression-free survival at 12 months, confirmed by central genetic testing.
A prospective cohort could determine whether patients with 9p21-loss tumors treated with cytarabine + ATR/CHK1 inhibitors have improved outcomes compared to those receiving other combinations.
A prospective cohort study following 350+ patients with advanced 9p21-loss tumors treated with cytarabine + ATR/CHK1 inhibitors, tracking response rates, toxicity, and survival over 24 months, with pre-treatment genetic and biomarker profiling.
A case-control study could compare the frequency of 9p21 loss in patients who responded to cytarabine + ATR/CHK1 inhibitors versus those who did not.
A case-control study comparing 110 patients with advanced cancer who achieved durable response to cytarabine + ATR/CHK1 inhibitor (≥6 months) versus 110 non-responders, matched for tumor type and prior therapy, with retrospective 9p21 deletion status assessed by NGS.
A cross-sectional analysis could correlate 9p21 loss with increased DNA damage and reduced repair capacity in tumors treated with cytarabine + ATR/CHK1 inhibitors.
A cross-sectional analysis of 160+ tumor biopsies from patients treated with cytarabine + ATR/CHK1 inhibitor, measuring 9p21 deletion status and levels of γH2AX, pCHK1, and RAD51 via immunohistochemistry, correlating with clinical response.